Mercy BioAnalytics, Inc., a pioneer in blood-based detection of early-stage cancer, today announced data from a groundbreaking study leveraging samples from the National Lung Screening Trial (NLST).
Accord BioPharma, Inc., the specialty division of Intas Pharmaceuticals, Ltd., focused on development of oncology, immunology, and critical care therapies, announced today the U.S. Food and Drug ...
Gastroenterologist Dr. Saurabh Sethi highlights pomegranate seeds as a superfood for gut health. These seeds act as ...
A new word is making the rounds in the business press: "anti-involution." In recent years, Chinese companies have built ...
Men diagnosed with prostate cancer have traditionally faced two choices: do nothing and hope the tumor doesn’t grow between ...
A new study has uncovered promising therapeutic strategies against one of the deadliest forms of prostate cancer.
Oncologists and urologists identified several barriers to treatment intensification for metastatic castration-sensitive ...
News Medical on MSN
Study uncovers promising therapeutic strategies against neuroendocrine prostate cancer
A new study has uncovered promising therapeutic strategies against one of the deadliest forms of prostate cancer.
Phase 3 ARENSENS clinical trial results were presented at JADPRO 2025, indicating darolutamide plus ADT improved rPFS in prostate cancer.
Johnson & Johnson is paying $3.05 billion to acquire Halda Therapeutics, obtaining a novel cell death platform while ...
(NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs ...
Company to Present and Host 1x1 Investor Meetings on Tuesday, December 2nd, 2025 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback